Literature DB >> 7901377

Extracellular 5-hydroxytryptamine concentration in rat hypothalamus after administration of fluoxetine plus L-5-hydroxytryptophan.

K W Perry1, R W Fuller.   

Abstract

Fluoxetine (10 mg kg-1, i.p.) caused a three- to fourfold increase in extracellular 5-hydroxytryptamine (5-HT) concentration measured by microdialysis in hypothalamus of freely moving rats. The addition of L-5-hydroxytryptophan at 20 or 40 mg kg-1, i.p. doses, magnified the increase in extracellular 5-HT to as much as 16 times basal levels, although these doses of L-5-hydroxytryptophan alone had only small effects on extracellular 5-HT. The increased formation of 5-HT following L-5-hydroxytryptophan administration appears to overcome homeostatic mechanisms that limit the increases in extracellular 5-HT caused by uptake inhibition.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7901377     DOI: 10.1111/j.2042-7158.1993.tb07105.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  15 in total

1.  Serotonin (5-HT) precursor loading with 5-hydroxy-l-tryptophan (5-HTP) reduces locomotor activation produced by (+)-amphetamine in the rat.

Authors:  Michael H Baumann; Zakia Williams; Dorota Zolkowska; Richard B Rothman
Journal:  Drug Alcohol Depend       Date:  2010-11-10       Impact factor: 4.492

2.  Comparison of female Fischer and Sprague-Dawley rats in the response to ketanserin.

Authors:  Chandra Suma Johnson Miryala; Cindy Hiegel; Lynda Uphouse
Journal:  Pharmacol Biochem Behav       Date:  2013-11-04       Impact factor: 3.533

3.  Enhancement of fluoxetine-dependent increase of extracellular serotonin (5-HT) levels by (-)-pindolol, an antagonist at 5-HT1A receptors.

Authors:  L J Dreshfield; D T Wong; K W Perry; E A Engleman
Journal:  Neurochem Res       Date:  1996-05       Impact factor: 3.996

4.  Slow-release delivery enhances the pharmacological properties of oral 5-hydroxytryptophan: mouse proof-of-concept.

Authors:  Jacob P R Jacobsen; Adrianna Oh; Rachel Bangle; Wendy L Roberts; Elizabeth L Royer; Nathan Modesto; Sonora A Windermere; Zixuan Yi; Rebecca Vernon; Manuel Cajina; Nikhil M Urs; Joshua C Snyder; Peter J Nicholls; Benjamin D Sachs; Marc G Caron
Journal:  Neuropsychopharmacology       Date:  2019-04-29       Impact factor: 7.853

5.  Blockage of muscle and neuronal nicotinic acetylcholine receptors by fluoxetine (Prozac).

Authors:  J García-Colunga; J N Awad; R Miledi
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

Review 6.  Adjunctive 5-Hydroxytryptophan Slow-Release for Treatment-Resistant Depression: Clinical and Preclinical Rationale.

Authors:  Jacob P R Jacobsen; Andrew D Krystal; K Ranga R Krishnan; Marc G Caron
Journal:  Trends Pharmacol Sci       Date:  2016-09-28       Impact factor: 14.819

7.  Inhibition of allergic inflammation by supplementation with 5-hydroxytryptophan.

Authors:  Hiam Abdala-Valencia; Sergejs Berdnikovs; Christine A McCary; Daniela Urick; Riti Mahadevia; Michelle E Marchese; Kelsey Swartz; Lakiea Wright; Gökhan M Mutlu; Joan M Cook-Mills
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-07-27       Impact factor: 5.464

Review 8.  The effect of increased serotonergic neurotransmission on aggression: a critical meta-analytical review of preclinical studies.

Authors:  Maria Carrillo; Lesley A Ricci; Glen A Coppersmith; Richard H Melloni
Journal:  Psychopharmacology (Berl)       Date:  2009-04-30       Impact factor: 4.530

9.  Differential effects of acute and chronic fluoxetine administration on the spontaneous activity of dopaminergic neurones in the ventral tegmental area.

Authors:  S Prisco; E Esposito
Journal:  Br J Pharmacol       Date:  1995-09       Impact factor: 8.739

Review 10.  Actions of 3,4-methylenedioxymethamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neurons.

Authors:  Gary A Gudelsky; Bryan K Yamamoto
Journal:  Pharmacol Biochem Behav       Date:  2007-10-16       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.